Artificial intelligence designs individual cancer vaccine has entered clinical trials

Recently, Transgene, in conjunction with NEC Corporation, announced that the immunotherapy TG4050, based on the personalized immunotherapy platform myvac ™, has entered phase 1 clinical trialsTG4050 is a viral-based therapeutic vaccine that expresses new antigens for tumors selected using NEC's AI algorithmTG4050 will be used in two clinical trials to treat ovarian cancer patients undergoing surgery and first-line chemotherapy, as well as patients with head and neck cancer after surgery and complementary treatment, to assess the safety and immunoogenicity of TG4050, and to pave the way for combination therapies with other therapiesNEC's new neoantigen prediction system based on artificial intelligence can identify and select patient-specific mutationsTG4050 expresses more than 30 new tumor antigens, selected by NEC's AI systemAI systems can be refined with proprietary immune data to accurately prioritize and select tumor-specific mutation antigens with high immunogenicityTransgene's personalized immunotherapy platform, myvac™ technology, aims to identify and destroy tumors by using their own cancer-specific genetic mutations to stimulate the patient's immune systemUsing their expertise in viral vectors, they integrated selected new antigen sequences into the genomes of viral vectors and initiated the clinical development of the individualized tumor vaccine TG4050for Transgene and NEC, the TG4050 vaccine is in phase 1 clinical trials, which represents:.combined with expertise in viral vectors and cutting-edge AI technology, TG4050 has pushed cancer vaccine development into the digital age;tailor-made new, individualized immunotherapy to patients by generating an immune response to tumor mutations in highly specific patients;, two Phase 1 clinical trials are currently being conducted at the Mayo Clinic and the University of Toulouse Cancer InstitutePicture: Tansgene.com
"The TG4050 is based on the MVA virus vector, which has been shown to be biologically active and capable of triggering an immune response to tumor antigens," said Philippe Archinard, Chairman and CEO of TransgeneThis treatment can turn the genetic characteristics of solid tumors into highly specific anti-cancer 'weapons' The intersection of immunotherapy and big data science is the product of TG4050, or may herald the beginning of a new generation in the fight against cancer Osamu Fujikawa, Senior Vice President, NEC Corporation, said: "The entry of TG4050 into clinical trials means that we are one step closer to the goal of 'providing AI-driven individualized immunotherapy for every patient' It is also hoped that TG4050 will have a positive impact on patients around the world "
medical technology is becoming more advanced, but the fear of cancer never seems to diminish, we look forward to hearing more good news about preventive and therapeutic vaccines, and we look forward to artificial intelligence technology to better advance the development of medicine for the benefit of mankind." References s1 s transgene to start clinical development lead myvacTM individualized immunotherapy, TG4050, in 2019, underits partnership NEC Retrieved Jan 8, 2020 from https:// 2, Transgene and NEC Start Two Clinical Trials with TG4050, an Individualed-Powered Cancer Vaccine for Ovarian and Head and Head and Neck CancerS Origins Origin S 8, 2020from from the https:// , https://#publications To Initiate Two Clinical Trials of its Lead myvac™ Individualized Immunotherapy T4050 Retrieved Jan 8, 2020 from https:// .5 s/https://